AIMS: Catheter ablation of ventricular tachycardia (VT) can be limited by haemodynamic instability. In these cases, substrate-based ablation is typically performed. An alternative is to perform activation and entrainment mapping during VT supported by a percutaneous left ventricular assist device (pVAD). We sought to compare the complication and success rates of pVAD-assisted VT ablation with scar-based techniques. METHODS AND RESULTS: Thirteen consecutive patients with haemodynamically unstable VT underwent pVAD-assisted ablation (pVAD group) and were retrospectively compared with 18-matched patients undergoing a substrate-based VT ablation (non-pVAD group). There was no significant difference in age or ejection fraction between the groups although pVAD patients tended to have more shocks in the preceding months. Procedure times were longer for the pVAD group. The number of monomorphic VTs induced was greater in the pVAD group (3.2 vs. 1.6, P= 0.04); however, after ablation, there was no difference in inducibility between the pVAD and non-pVAD group (10 of 13 vs. 12 of 18; 77 vs. 67%, P = 0.69). There was no difference in acute complications including stroke or death. At 9 ± 3 months, 1-year freedom from implantable cardioverter-defibrillator (ICD) shocks/therapies for sustained VT were similar (P= 0.96). In multivariable analysis, the absence of atrial fibrillation (hazard ratio=0.15, P= 0.04) was associated with a lower incidence of ICD shocks. CONCLUSIONS: In high-risk patients, pVAD-assisted VT ablation guided by activation and entrainment mapping is a feasible alternative to substrate mapping and allows outcomes comparable to substrate mapping.
AIMS: Catheter ablation of ventricular tachycardia (VT) can be limited by haemodynamic instability. In these cases, substrate-based ablation is typically performed. An alternative is to perform activation and entrainment mapping during VT supported by a percutaneous left ventricular assist device (pVAD). We sought to compare the complication and success rates of pVAD-assisted VT ablation with scar-based techniques. METHODS AND RESULTS: Thirteen consecutive patients with haemodynamically unstable VT underwent pVAD-assisted ablation (pVAD group) and were retrospectively compared with 18-matched patients undergoing a substrate-based VT ablation (non-pVAD group). There was no significant difference in age or ejection fraction between the groups although pVADpatients tended to have more shocks in the preceding months. Procedure times were longer for the pVAD group. The number of monomorphic VTs induced was greater in the pVAD group (3.2 vs. 1.6, P= 0.04); however, after ablation, there was no difference in inducibility between the pVAD and non-pVAD group (10 of 13 vs. 12 of 18; 77 vs. 67%, P = 0.69). There was no difference in acute complications including stroke or death. At 9 ± 3 months, 1-year freedom from implantable cardioverter-defibrillator (ICD) shocks/therapies for sustained VT were similar (P= 0.96). In multivariable analysis, the absence of atrial fibrillation (hazard ratio=0.15, P= 0.04) was associated with a lower incidence of ICD shocks. CONCLUSIONS: In high-risk patients, pVAD-assisted VT ablation guided by activation and entrainment mapping is a feasible alternative to substrate mapping and allows outcomes comparable to substrate mapping.
Authors: K Soejima; M Suzuki; W H Maisel; C B Brunckhorst; E Delacretaz; L Blier; S Tung; H Khan; W G Stevenson Journal: Circulation Date: 2001-08-07 Impact factor: 29.690
Authors: Angel Arenal; Esteban Glez-Torrecilla; Mercedes Ortiz; Julian Villacastín; Javier Fdez-Portales; Elena Sousa; Silvia del Castillo; Leopoldo Perez de Isla; Javier Jimenez; Jesus Almendral Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Corinna B Brunckhorst; Etienne Delacretaz; Kyoko Soejima; William H Maisel; Peter L Friedman; William G Stevenson Journal: Circulation Date: 2004-08-02 Impact factor: 29.690
Authors: Nilesh Mathuria; Geru Wu; Francia Rojas-Delgado; Mossaab Shuraih; Mehdi Razavi; Andrew Civitello; Leo Simpson; Guilherme Silva; Suwei Wang; MacArthur Elayda; Bharat Kantharia; Steve Singh; O H Frazier; Jie Cheng Journal: J Interv Card Electrophysiol Date: 2016-08-06 Impact factor: 1.900
Authors: Vaibhav R Vaidya; Christopher V Desimone; Malini Madhavan; Amit Noheria; Mohammed Shahid; Jacob Walters; Dorothy J Ladewig; Susan B Mikell; Susan B Johnson; Scott H Suddendorf; Samuel J Asirvatham Journal: J Cardiovasc Electrophysiol Date: 2014-06-03
Authors: Binyamin Ben Avraham; Marisa Generosa Crespo-Leiro; Gerasimos Filippatos; Israel Gotsman; Petar Seferovic; Tal Hasin; Luciano Potena; Davor Milicic; Andrew J S Coats; Giuseppe Rosano; Frank Ruschitzka; Marco Metra; Stefan Anker; Johann Altenberger; Stamatis Adamopoulos; Yaron D Barac; Ovidiu Chioncel; Nicolaas De Jonge; Jeremy Elliston; Maria Frigeiro; Eva Goncalvesova; Avishay Grupper; Righab Hamdan; Yoav Hammer; Loreena Hill; Osnat Itzhaki Ben Zadok; Miriam Abuhazira; Jacob Lavee; Wilfried Mullens; Sanemn Nalbantgil; Massimo F Piepoli; Piotr Ponikowski; Arsen Ristic; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Steven Tsui; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-14
Authors: Bartłomiej Szafron; Radosław Hugon Smoczyński; Dominik Drobiński; Agnieszka Pawlak; Dariusz Wojciechowski; Irena Maria Liszka; Anna Witkowska; Zygmunt Kaliciński; Robert Gil; Piotr Suwalski Journal: Kardiochir Torakochirurgia Pol Date: 2015-03-31